<- Go Home
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Market Cap
$232.1M
Volume
125.0K
Cash and Equivalents
$31.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.52
52 Week Low
$5.55
Dividend
N/A
Price / Book Value
12.22
Price / Earnings
-6.62
Price / Tangible Book Value
12.22
Enterprise Value
$200.4M
Enterprise Value / EBITDA
N/A
Operating Income
-$27.6M
Return on Equity
188.03%
Return on Assets
-68.50
Cash and Short Term Investments
$31.6M
Debt
N/A
Equity
$18.4M
Revenue
N/A
Unlevered FCF
-$6.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium